Loading
Aprea Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 02 Feb 2026.
Aprea Therapeutics, Inc.: what insiders have been doing
Aprea Therapeutics, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Aprea Therapeutics, Inc. logged 14 filings by 10 insiders.
The flow runs one way only: 3 insiders bought (4 purchases totalling €52k) and nobody sold on the market. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 1 finance chief, 1 senior executive and 1 chief executive. One trade stands out by size: a purchase of €21k from Duey Marc, disclosed on 11 December 2025.
Within a 30-day window, 4 purchases overlapped with buying by a second insider. Purchases made close together by different insiders form what is called a cluster. The last purchase on record was published on 2 February 2026, which is 258 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 14 filings, this issuer sits below that mark. Since 2021, the database holds 21 purchases and 4 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -12.6 m USD.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
99
Thresholds
n/a
Buy Volume
€391,669
21 ops. · all time
Sell Volume
€169,704
4 ops. · all time
Who traded when
BuySaleJohn P. Hamill2 buys
Oren Gilad2 buys
Marc Duey1 buy
Since the insiders bought
- +25.0%Entry US$0.67 · Close at T+90 US$0.84
- +25.0%Entry US$0.67 · Close at T+90 US$0.84
- -33.9%Entry US$0.94 · Close 15 Oct 2026 US$0.62
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.60
Analyst consensus
3 analysts1.33/5
US$1.20Target US$3.73(+522%)US$5.00
Income statement
EBITDA-US$13.2M
Net income-US$12.6M0.0% margin
Valuation
PER (forward)-1.8x
P/Book0.2x
Beta1.63
Balance sheet & cash
Market capUS$7.6M
Free Cash Flow-US$12.9M
Profitability & ownership
ROE-46.1%
ROA-27.7%
% insiders9.2%
% institutions18.8%
Last declaration on 17 June 2026
Declarations99 total
3,135 sharesCommon StockSEC:0001104659-26-075278:0
3,135 sharesCommon StockSEC:0001104659-26-075279:0
3,135 sharesCommon StockSEC:0001104659-26-075281:0
3,135 sharesCommon StockSEC:0001104659-26-075282:0
3,135 sharesCommon StockSEC:0001104659-26-075283:0
3,135 sharesCommon StockSEC:0001104659-26-075284:0
3,135 sharesCommon StockSEC:0001104659-26-075286:0
20,175 shares0Common StockSEC:0001104659-26-028656:0
10,095 shares0Common StockSEC:0001104659-26-028653:0
28,100 shares@ US$0.8946.9% of flowCommon StockSEC:0001104659-26-009206:0
Canonical exit: 30 Apr 2026 (T+90)
5,700 shares@ US$0.8919.1% of flowCommon StockSEC:0001104659-26-009203:0
Canonical exit: 30 Apr 2026 (T+90)
5,000 shares@ US$1.16522.6% of flowCommon StockSEC:0001104659-25-120155:0
Canonical exit: 10 Mar 2026 (T+90)
1,045 shares0Common StockSEC:0001104659-25-057818:0
1,045 shares0Common StockSEC:0001104659-25-057811:0
1,045 shares0Common StockSEC:0001104659-25-057823:0
1,045 shares0Common StockSEC:0001104659-25-057821:0
1,045 shares0Common StockSEC:0001104659-25-057815:0
1,045 shares0Common StockSEC:0001104659-25-057806:0
1,045 shares0Common StockSEC:0001104659-25-057813:0
3,003 shares@ US$1.8711.4% of flowCommon StockSEC:0001104659-25-031991:0
Canonical exit: 2 Jul 2025 (T+90)
6,725 shares0Common StockSEC:0001104659-25-029914:0
3,365 shares0Common StockSEC:0001104659-25-029920:0
25 of 99 declarations
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. (Nasdaq: APRE) is a U.S.-based clinical-stage biopharmaceutical company listed on the NASDAQ market in the United States. Headquartered in Doylestown, Pennsylvania, the company is focused on precision oncology and the development of targeted cancer therapies built around DNA damage response (DDR) biology and synthetic lethality. Its strategy is to identify vulnerabilities in cancer cells and translate them into small-molecule therapies that may deliver antitumor activity while aiming to reduce damage to healthy tissue. ([ir.aprea.com](https://ir.aprea.com/investor-relations/?utm_source=openai))
Aprea’s roots trace back to Aprea Therapeutics AB, which was originally incorporated in 2002 and began principal operations in 2006. The U.S. company Aprea Therapeutics, Inc. was incorporated in June 2016, reflecting the evolution of the business from its earlier Scandinavian origins into a Nasdaq-listed oncology platform. The company’s development history and current structure suggest a long-term scientific focus rather than a commercial-stage model, with value creation dependent on clinical execution, biomarker selection, and data readouts. ([ir.aprea.com](https://ir.aprea.com/static-files/ca97aed5-79ff-4762-8b27-6960f910c102?utm_source=openai))
Read moreShow less
The company’s pipeline is currently anchored by two lead clinical programs. APR-1051 is an oral, selective WEE1 kinase inhibitor being evaluated in the ACESOT-1051 study in solid tumors. ATRN-119 is an oral ATR inhibitor under clinical development for solid-tumor indications as well. Both programs sit within Aprea’s broader DDR-focused platform, and both are designed to exploit cancer-specific vulnerabilities. For investors, this means the company is not a diversified oncology player; rather, it is a highly specialized, program-driven developer whose outlook depends on the quality of emerging clinical data. ([aprea.com](https://aprea.com/aprea-therapeutics-pipeline/?utm_source=openai))
In competitive terms, Aprea operates in a crowded precision-oncology landscape dominated by large pharmaceutical companies and better-capitalized biotech peers. As a result, the company’s differentiation comes from scientific selectivity, early clinical signals, and intellectual property strength rather than market share or commercial reach. Aprea has emphasized its global patent portfolio, which supports its WEE1 and ATR programs and is important for protecting future optionality. The company remains pre-commercial and therefore has no marketed product revenue base at this stage. ([ir.aprea.com](https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-strengthens-global-patent-portfolio-dna?utm_source=openai))
Recent developments have been material. In 2026, Aprea reported a confirmed partial response in the ongoing ACESOT-1051 trial for APR-1051, reinforcing early clinical proof-of-concept. The company also announced an oversubscribed private placement expected to generate about $30 million in gross proceeds, and it reported first-quarter 2026 financial results in May 2026. Earlier, Aprea received a Nasdaq non-compliance notice in January 2026 related to minimum bid price requirements, a key listing risk that investors should monitor closely. Overall, the story remains one of clinical-stage optionality, capital needs, and execution risk, with upcoming data releases likely to be the principal catalysts. ([nasdaq.com](https://www.nasdaq.com/press-release/aprea-therapeutics-highlights-positive-emerging-clinical-activity-wee1-inhibitor-apr?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
